4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-23-014273
Chief Executive Officer sold 25,000 shares at an average $48.25 ($1,206,243)
- Chief Executive Officer acquired 25,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2023-02-27 | Option exercise | +25,000 | $19.12 | $478,000 | 400,988 | D |
| Kulkarni Samarth Chief Executive Officer | 2023-02-27 | Sale | −10,180 | $47.71 | $485,710 | 390,808 | D |
| Kulkarni Samarth Chief Executive Officer | 2023-02-27 | Sale | −13,720 | $48.57 | $666,415 | 377,088 | D |
| Kulkarni Samarth Chief Executive Officer | 2023-02-27 | Sale | −1,100 | $49.20 | $54,118 | 375,988 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2023-02-27 | Option exercise · Stock Option (Right to Buy) | −25,000 | 154,582 | D | ||
| Open-market sales · 25,000 sh · avg $48.25 · $1,206,243 | |||||||
Loading xslF345X03/doc4.xml…